DEFINITIONS ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES SATISFACTION AND DISCHARGE PARTICULAR COVENANTS OF THE COMPANY LISTS OF HOLDERS AND REPORTS BY THE COMPANY AND THE TRUSTEE DEFAULTS AND REMEDIES CONCERNING THE TRUSTEE...Emergent BioSolutions Inc. • January 29th, 2014 • Pharmaceutical preparations • New York
INDENTURE dated as of January 29, 2014 between Emergent BioSolutions Inc., a Delaware corporation, as issuer (the "Company," as more fully set forth in Section 1.01) and Wells Fargo Bank, National Association, a national banking association, as trustee (the "Trustee," as more fully set forth in Section 1.01).
EMERGENT BIOSOLUTIONS INC.Purchase Agreement • January 29th, 2014 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
Emergent BioSolutions Inc., a Delaware corporation (the "Company"), confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), J.P. Morgan Securities LLC ("JP Morgan") and each of the other Initial Purchasers named in Schedule A hereto (collectively, the "Initial Purchasers," which term shall also include any initial purchaser substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch and JP Morgan are acting as representatives (in such capacity, the "Representatives"), with respect to (i) the sale by the Company and the purchase by the Initial Purchasers, acting severally and not jointly, of the respective principal amounts set forth in said Schedule A of $215,000,000 aggregate principal amount of the Company's 2.875% Convertible Senior Notes due 2021 (the "Initial Securities") and (ii) the grant by the Company to the Initial Purchasers, acting severally and not jointly, of the option to purchase all or any part of an addit
